Search

Your search keyword '"Pugliese, N."' showing total 4 results
Start Over Author "Pugliese, N." Journal leukemia research
4 results on '"Pugliese, N."'

3. Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia

Author

Giovanni Martinelli, Nicola Esposito, Santa Errichiello, Concetta Quintarelli, Simona Caruso, Antonio M. Risitano, Marco Picardi, Irene Colavita, Luigia Luciano, Fabrizio Pane, Simona Pagliuca, Giuseppe Saglio, Maddalena Raia, Novella Pugliese, Biagio De Angelis, Quintarelli, Concetta, DE ANGELIS, Biagio, Errichiello, S, Caruso, S, Esposito, N, Colavita, I, Raia, M, Pagliuca, S, Pugliese, N, Risitano, ANTONIO MARIA, Picardi, Marco, Luciano, L, Saglio, G, Martinelli, G, and Pane, Fabrizio

Subjects
Cancer Research, Ruxolitinib, Stromal cell, medicine.drug_class, Drug Evaluation, Preclinical, Pharmacology, Tyrosine-kinase inhibitor, Inhibitory Concentration 50, Stroma, Bone Marrow, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Nitriles, Tumor Cells, Cultured, Humans, Medicine, Protein Kinase Inhibitors, business.industry, Drug Synergism, Imatinib, Hematology, medicine.disease, respiratory tract diseases, Pyrimidines, Oncology, Drug Resistance, Neoplasm, Pyrazoles, Stromal Cells, K562 Cells, business, Tyrosine kinase, Chronic myelogenous leukemia, medicine.drug, K562 cells
Abstract

a b s t r a c t The IC50 of TKIs is significantly increased when BCR-ABL+ K562 cell line is cultured in stroma conditioned media produced by BM mesenchymal cells. In particular, while the Imatinib IC50 in the stromal co- cultures was well above the in vivo through levels of the drug, the IC50s of second generation TKIs were still below their through levels. Moreover, we provide a formal comparison of the synergy between first and second generation TKIs with the JAK inhibitor Ruxolitinib to overcome BM stroma related TKI resistance. Taken together, our data provide a rationale for the therapeutic combination of TKIs and Ruxolitinib with the aim to eradicate primary BCR-ABL+ cells homed in BM niches.

Published
2014
Full Text
View/download PDF

4. Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia.

Author

Quintarelli C, De Angelis B, Errichiello S, Caruso S, Esposito N, Colavita I, Raia M, Pagliuca S, Pugliese N, Risitano AM, Picardi M, Luciano L, Saglio G, Martinelli G, and Pane F

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow pathology, Drug Evaluation, Preclinical, Drug Synergism, Humans, Inhibitory Concentration 50, K562 Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Nitriles, Pyrimidines, Stromal Cells pathology, Stromal Cells physiology, Tumor Cells, Cultured, Antineoplastic Combined Chemotherapy Protocols pharmacology, Bone Marrow physiology, Drug Resistance, Neoplasm drug effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Protein Kinase Inhibitors pharmacology, Pyrazoles pharmacology
Abstract

The IC50 of TKIs is significantly increased when BCR-ABL+ K562 cell line is cultured in stroma conditioned media produced by BM mesenchymal cells. In particular, while the Imatinib IC50 in the stromal co-cultures was well above the in vivo through levels of the drug, the IC50s of second generation TKIs were still below their through levels. Moreover, we provide a formal comparison of the synergy between first and second generation TKIs with the JAK inhibitor Ruxolitinib to overcome BM stroma related TKI resistance. Taken together, our data provide a rationale for the therapeutic combination of TKIs and Ruxolitinib with the aim to eradicate primary BCR-ABL+ cells homed in BM niches., (Copyright © 2013 Elsevier Ltd. All rights reserved.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results